Shares of Insulet Corp. PODD shed 1.03% to $265.65 Tuesday, on what proved to be an all-around grim trading session for the ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Insulet Corporation ( NASDAQ:PODD ) saw a double-digit share price rise of over 10% in the past couple of months on ...
Insulet (NASDAQ:PODD – Get Free Report) had its target price increased by investment analysts at TD Cowen from $264.00 to ...
Bank of America Securities analyst Travis Steed maintained a Buy rating on Insulet (PODD – Research Report) yesterday and set a price target of ...
TD Cowen raised the firm’s price target on Insulet (PODD) to $324 from $264 and keeps a Buy rating on the shares. The firm thinks Insulet will ...
Buying $100 In PODD: If an investor had bought $100 of PODD stock 10 years ago, it would be worth $598.02 today based on a ...
TD Cowen raised the firm’s price target on Insulet (PODD) to $324 from $264 and keeps a Buy rating on the shares. The firm thinks Insulet will continue to deliver “beat-and-raise performances ...
Investor's Business Daily on MSN21h
Insulin Device Maker Has Analysts Turning BullishInsulet stock is near a buy point after gapping up on earnings. The company increased its full year sales guidance.
Intuitive Surgical (ISRG), and Insulet (PODD) stocks were cited as top MedTech stock picks for 2025 by J.P. Morgan. Read more ...
Investor's Business Daily on MSN2h
Lantheus Stock Doubled In A Year Amid Wide Use Of Its AI-Enabled Medical DevicesArtificial intelligence is the watchword for investors, but some analysts also see strength this year in the medical sector.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback